We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Stratos Biosystems Announces the Exclusive License for UV Manufacturing of Mass Spectrometry Biochips

Read time: Less than a minute

Stratos Biosystems, LLC, has announced that it has received exclusive license in the field of life science mass spectrometry for U.S. Patent 5,514,501 from the National Institute of Standards and Technology (NIST).

The patent titled "Process for UV-photo patterning of thiolate monolayers self-assembled on gold, silver and other substrates" provides Stratos Biosystems with the exclusive rights in the United States for utilizing this process for the production of surfaces or substrates used in life science mass spectrometry.

The licensing of this patent adds to the growing portfolio of intellectual property that Stratos has assembled to support the products based on the Company's electro-cleavable surface chemistries and EC-Affinity Biochips.

UV photo patterning gives Stratos Biosystems the cost-efficient method for creating densely arrayed biochips for mass spectrometry identification of proteins.

Mass spectrometry protein identification is critical in two major efforts underway at life science research facilities around the World: early disease detection and research on the effects of pharmaceuticals, chemicals, metals, pollutants and toxicants on humans, animals, insects, plants and other biological systems.

"We are very happy to have secured this extremely valuable patent. It will allow us to significantly impact research based on the capture, identification and validation of proteins released into the blood by diseased cells or cancer," said Allan Stephan, CEO Stratos Biosystems.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.